Business Wire
11 Jun 2026, 12:41 UTC · 2h ago
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
Business Wire
11 Jun 2026, 12:41 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Top 1 mover · tap to explore
What the story claims
1 claim · each scored for market impact
Chiesi Group has completed the acquisition of KalVista Pharmaceuticals. — Acquisitions typically indicate growth in pipeline and capabilities, specifically strengthening Chiesi's Rare Diseases business unit.
+0.40Which stocks this story touches
Continue reading
6 related stories
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
WSJ
7h ago
